BRAF and melanoma: The advent of immune checkpoint inhibitors (ICIs) and targeted therapy with BRAF/MEK inhibitors (BRAFi/MEKi) has profoundly transformed the landscape of melanoma treatment, leading to marked improvements in outcomes for patients with metastatic melanoma (MM) [[1], [2], [3]].